Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET (IDEALPET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01109992
Recruitment Status : Completed
First Posted : April 23, 2010
Results First Posted : October 25, 2018
Last Update Posted : October 25, 2018
Sponsor:
Information provided by (Responsible Party):
Sharmila Dorbala, MBBS, Brigham and Women's Hospital

Brief Summary:
This is a single-center study of subjects undergoing clinically indicated heart scans for evaluation of known or suspected heart disease. We will also include 10 healthy subjects without known heart disease. We would like to study stress testing of the heart using exercise and a medication called regadenoson. Imaging of the heart will be performed.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: Exercise plus Regadenoson (Lexercise) Drug: Regadenoson (Lexiscan) Phase 4

Detailed Description:

Regadenoson is stress agent approved by the FDA for use with myocardial perfusion imaging with technetium-99m single photon emission computed tomography (SPECT) in patients that are unable to exercise adequately. We would like to study Regadenoson in conjunction with Exercise Rubidium-82 positron emission tomography myocardial perfusion imaging (PET MPI). Regadenoson is not approved by FDA for use with Rubidium-82 PET MPI. Also, we would like to study a novel stress protocol of Regadenoson combined with symptom limited exercise stress (not FDA approved).

The objectives of this study are to assess the tolerability and safety of combined symptom limited exercise stress test with Lexiscan (Lexercise PET) compared to Lexiscan alone (Lexiscan PET), to assess image quality of Lexercise compared to Lexiscan PET and to compare relative and absolute myocardial perfusion imaging with Lexercise compared to Lexiscan PET to identify CAD.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Integrated Dual Exercise and Lexiscan PET: IDEAL PET
Study Start Date : February 2011
Actual Primary Completion Date : June 6, 2017
Actual Study Completion Date : June 6, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Regadenoson

Arm Intervention/treatment
Active Comparator: Regadenoson (Lexiscan)
Regadenoson Rubidium-82 Positron Emission Tomography
Drug: Regadenoson (Lexiscan)
Regadenoson Rubidium-82 Positron Emission Tomography

Experimental: Exercise + Regadenoson (Lexercise)
Exercise plus Regadenoson (Lexercise) Rubidium-82 Positron Emission Tomography
Drug: Exercise plus Regadenoson (Lexercise)
Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
Other Name: Exercise plus Lexiscan




Primary Outcome Measures :
  1. Safety and Tolerability of Combined Exercise and Regadenoson Stress [ Time Frame: Day of the research scan during the stress test ]
    1. Count of subjects with ischemic ECG changes is reported
    2. Count of subjects with systolic blood pressure decrease > 20 mm Hg is reported
    3. Count of subjects with abnormal serum troponin T levels is reported
    4. Radiation dose to the staff will be measured using personal dosimeters after the Lexiscan as well as the Lexercise PET study.


Secondary Outcome Measures :
  1. Image Quality: Heart to Liver Ratio of Counts [ Time Frame: Week 1 (day of the clinical scan), and Week 2 (day of the research scan) ]

    Sub-diaphragmatic activity: Heart to Liver Ratio was measured on the rubidium-82 and N-13 ammonia scans. Since this measure is a ratio it has no units. Mean and Standard Deviation of Ratio is reported for each group.

    This was measured on the clinical scan and on the research scan which were performed about 2 weeks apart in most subjects.


  2. Changes in Left Ventricular Function With Dual Exercise and Regadenoson PET [ Time Frame: Week 1 (day of the clinical scan), and Week 2 (day of the research scan) ]

    Left ventricular ejection fraction (LVEF) at stress was measured at Stress scan 1 (regadenoson) and Stress scan 2 (regadenoson or exercise + regadenoson).

    This was measured on the clinical scan and on the research scan which were performed about 2 weeks apart in most subjects.


  3. Peak Stress Myocardial Blood Flow [ Time Frame: Week 1 (day of the clinical scan), and Week 2 (day of the research scan) ]
    Myocardial Blood Flow Measured at Peak Hyperemia With Regadenoson or Immediately After Exercise + Regadenoson This was measured on the clinical scan and on the research scan which were performed about 2 weeks apart in most subjects.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age > 18 years
  • Clinically indicated N-13 ammonia PET study or ten healthy volunteers
  • Known coronary artery disease (prior percutaneous coronary intervention, prior coronary artery bypass surgery or Q wave MI on ECG) or intermediate to high pretest likelihood of CAD
  • Able to exercise on a treadmill
  • Able and willing to provide informed consent to participate in the study

Exclusion Criteria:

  • Contraindications to exercise stress testing such as, unstable angina, known severe left main coronary artery stenosis, severe heart failure, uncontrolled arrhythmias, symptomatic hypotension or severe hypertension (systolic blood pressure < 90 or > 200 mmHg, respectively), or > 1st degree atrioventricular block in the absence of a functioning pacemaker.
  • Subject requires emergent cardiac medical intervention or catheterization after the clinical study.
  • Documented myocardial infarction (MI) ≤ 30 days prior to enrollment.
  • History of percutaneous coronary intervention (PCI) ≤ 4weeks prior to enrollment.
  • History of coronary artery bypass graft (CABG) ≤ 8 weeks prior to enrollment.
  • History of heart transplantation.
  • Allergy or intolerance to aminophylline or regadenoson
  • Known severe or oxygen dependent bronchoconstrictive or bronchospastic lung disease [e.g., asthma, wheezing, chronic obstructive pulmonary disease (COPD), etc.].
  • Severe LV dysfunction, with ejection fraction of < 30%
  • Serious non-cardiac medical illness (e.g., disseminated malignancy, severe neurological dysfunction at time of baseline PET study) or a social situation which will preclude research study participation
  • History of Seizures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01109992


Locations
Layout table for location information
United States, Massachusetts
Brigham and Womens' Hospital
Boston, Massachusetts, United States, 02421
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Sharmila Dorbala, MBBS Brigham and Women's Hospital
  Study Documents (Full-Text)

Documents provided by Sharmila Dorbala, MBBS, Brigham and Women's Hospital:

Publications:
Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO Jr, Cerqueira MD, St John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003 Sep 16;108(11):1404-18.

Layout table for additonal information
Responsible Party: Sharmila Dorbala, MBBS, Director, Nuclear Cardiology, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01109992     History of Changes
Other Study ID Numbers: BWH
First Posted: April 23, 2010    Key Record Dates
Results First Posted: October 25, 2018
Last Update Posted: October 25, 2018
Last Verified: September 2018

Keywords provided by Sharmila Dorbala, MBBS, Brigham and Women's Hospital:
coronary artery disease
exercise
regadenoson
positron emission tomography

Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Regadenoson
Adenosine A2 Receptor Agonists
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs